Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Above 18 years old; * Patients with measurable, histologically or clinical proven, inoperable HCC; * Patients wtih measurable lesion and proved by independent radiology committee(IRC); * Child-Pugh (CP) score of 7 or less； * Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less; * Patients had not received prior systemic treatments for HCC; * Life expectancy at least 3 months; * Adequate hepatic and renal function; * Adequate hematologic function (platelet count,≥75×109per liter;hemoglobin ≥9.0g per deciliter;neutrophil≥1.5×109per liter,); * Prothrombin time international normal. Exclusion Criteria: * Patients received operate in 3 months; * Patients received transcatheter arterial chemoembolization（TACE） in 4 weeks; * Patients had received systemic therapy; * Patients had prior treatment with sorafenib; * Central nervous system(CNS) involvement; * Severe or mild-degree ascitic fluid; * Main portal vein tumor thrombus; * Inferior venae cava tumor thrombus.